AI: Challenges, Opportunities and Impact for Drug Discovery Teams

Life Sciences, Drug Discovery & Development,
  • Tuesday, October 31, 2023

Discover an informative webinar delving into the challenges and opportunities of artificial intelligence (AI) and machine learning (ML) on drug discovery teams. Everyone wants to shorten timelines, cut costs and reduce risk by implementing the silver bullet of AI and ML into their drug discovery workflow, but scientific breakthroughs are only as trustworthy as the data that initiates them.

With the average small molecule drug taking up to 15 years to get to market with a $1–2 billion investment and a 90% failure rate, companies are understandably eager to improve the process with the help of speedy, reliable computers.

In fact, the prevailing sentiment of AI and ML can be summarized by a line from a Forbes Technology Council article: “No matter how limited or simple the prior datasets, AI can come to a more accurate calculation and conclusion than a human mind.”

What is the real value-add of AI and ML for drug developers? Featured speakers from CAS, architect of the world’s largest human-curated scientific database, share the challenges and opportunities of artificial intelligence; what to keep in mind during the AI implementation journey; and its potential impact on drug discovery teams.

Join this webinar to learn about the strengths, limitations and impact of AI and ML techniques on drug discovery teams.

Speakers

Jeffrey Wilson, CAS

Jeffrey Wilson, PhD, Senior Manager, Data Science, CAS

Dr. Jeffrey Wilson leads CAS’ Data Analysis & Insights department and has more than 20 years of experience in scientific data analysis. Jeff’s department of data scientists improves CAS processes, solutions and business decisions by implementing the latest technology to get maximum benefit from the organization’s data.

He obtained his PhD in Chemistry at the University of Iowa.

Message Presenter
Gary Gustafson, CAS

Gary Gustafson, PhD, Senior Customer Success Specialist, CAS

Dr. Gary Gustafson spent 25 years as a Medicinal Chemist in the industry and was part of a team that produced the recently FDA-approved drug, Olutasidenib. Since joining CAS in 2019, Gary has helped scientists derive maximum benefit from CAS solutions.

He obtained his PhD in Chemistry at Brown University and completed a Postdoctoral Position in Organic Chemistry and Biochemistry at the University of Virginia.

Message Presenter

Who Should Attend?

This webinar will appeal to professionals in the following roles:

  • Medicinal Chemist
  • Molecular Biologist
  • Head of Discovery Biology
  • Head of Chemistry in drug discovery
  • Head of R&D in drug discovery

What You Will Learn

Attendees will gain insights into:

  • The important concepts to consider when implementing AI technology in drug discovery team workflow
  • The strengths, limitations and impact of artificial intelligence (AI) and machine learning (ML) techniques on drug discovery teams

Xtalks Partner

CAS

CAS is a leader in scientific information solutions, partnering with innovators around the world to accelerate scientific breakthroughs. CAS employs over 1,400 experts who curate, connect, and analyze scientific knowledge to reveal unseen connections. For over 100 years, scientists, patent professionals, and business leaders have relied on CAS solutions and expertise to provide the hindsight, insight, and foresight they need so they can build upon the learnings of the past to discover a better future. CAS is a division of the American Chemical Society. Connect with us at cas.org.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account